A metaphase cell positive for the bcr/abl rearrangement (associated with chronic myelogenous leukemia) using FISH. The ... chronic myelogenous leukemia, acute lymphoblastic leukemia, Cri-du-chat, Velocardiofacial syndrome, and Down syndrome. FISH on ... An example is the detection of BCR/ABL translocations, where the secondary color indicates disease. This variation is often ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ...
"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia". Oncogene. 13 (2): 247-54. PMID ... "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat. Med. 2 (5): 561-6. ... Different inhibitors have been designed to target different kinases: inhibition of BCR/ABl constitutes the basis of the ... Leukemia. 23 (8): 1441-5. doi:10.1038/leu.2009.50. PMID 19295546. Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, ...
Drugs known as tyrosine kinase inhibitors target BCR-ABL, and are the standard treatment for chronic myelogenous leukemia. ... Thus, trastuzumab has been a standard-of-care treatment in both metastatic and early stage HER2-positive breast cancer cases. ... However, after imatinib was used as the first-line therapy, several BCR-ABL-dependent and BCR-ABL-independent mechanisms of ... The majority of chronic myelogenous leukemia cases are caused by a rearrangement between chromosomes 9 and 22. This results in ...
"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome", Blood, 45 (3): 321-34, PMID 163658 Drexler ... presumably due to the downregulation of surface adhesion molecules by bcr:abl. However, another study suggests that bcr:abl ... The cells are non-adherent and rounded, are positive for the bcr:abl fusion gene, and bear some proteomic resemblance to both ... K562 cells are of the erythroleukemia type, and the cell line is derived from a 53-year-old female chronic myelogenous leukemia ...
"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia". Oncogene. 13 (2): 247-54. PMID ... "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat. Med. 2 (5): 561-6. ... inhibition of BCR/ABl constitutes the basis of the functioning of drugs like imatinib[7] ... "A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo". Blood. 99 (11): 3885-91. doi: ...
... designed specifically for the bcr-abl fusion protein that is characteristic for Philadelphia chromosome-positive leukemias ( ... chronic myelogenous leukemia and occasionally acute lymphocytic leukemia). Imatinib is substantially different from previous ... an antiviral drug 5-HT3 antagonists Acetylcholine receptor agonists Angiotensin receptor antagonists Bcr-Abl tyrosine-kinase ...
Schiffer CA (July 2007). "BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia". N. Engl. J. Med. 357 (3): 258- ... and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal ... In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of abl with bcr (breakpoint cluster ... "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase". Nat. Med. ...
... is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia. ... "Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia". 5 Sep 2012. "Bosulif : ... in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib ... October 2012). "Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA ...
"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL ... chromosome-positive (Ph+) cells at diagnosis, including so-called major route abnormalities (a second Ph chromosome, trisomy 8 ... Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form ... Chronic Myeloid Leukemia at American Cancer Society CML information from The Leukemia & Lymphoma Society Chronic Myelocytic ...
BCR-ABL (Chronic Myeloid Leukemia), BRCA1 / BRCA2 (Breast/Ovarian Cancer), BRAF V600E (Melanoma/Colorectal Cancer), CA-125 ( ... BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood. 117 ... For instance, in the 1960s, researchers discovered the majority of patients with chronic myelogenous leukemia possessed a ... For many years, the BCR-ABL was simply used as a biomarker to stratify a certain subtype of leukemia. However, drug developers ...
... , sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia (CML) which has the ... It is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl ... Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. Nilotinib has a number of ... "FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia". U.S. Food and Drug ...
... are a chronic myelogenous leukemia (CML) cell line used for biomedical research. Like all cancer cell lines, it is ... Like other CML cells lines (e.g., K562) KBM-7 cells are positive for the Philadelphia chromosome harboring the BCR-ABL ... "Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line ... KBM-7 cells were derived from a 39-year-old man with chronic myeloid leukemia in blast crisis. The original cell line contained ...
... is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive ... It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family ... and adults with newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase ... chronic myeloid leukemia (CML) in the chronic phase. Approval was based on data from 97 pediatric participants with chronic ...
... induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL ... Burke, B.A.; Carroll, M. (2010). "BCR-ABL: A multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia". Leukemia ... Nimmanapalli, R.; Bhalla, K. (2002). "Novel targeted therapies for Bcr-Abl positive acute leukemias: Beyond STI571". Oncogene. ... "Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia". British Journal of ...
... s (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). ... "BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review". ... Bcr-Abl dependent mechanisms include over expression or amplification of the Bcr-Abl gene and point mutations within the Bcr- ... Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that ...
... designed specifically for the bcr-abl fusion protein that is characteristic for Philadelphia chromosome-positive leukemias ( ... chronic myelogenous leukemia and occasionally acute lymphocytic leukemia). Imatinib is substantially different from previous ...
... a characteristic abnormality in chronic myelogenous leukemia (CML) and rarely in some other leukemia forms. The BCR-ABL ... "Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines". Int. J. Hematol. 65 (2 ... Second generation BCR-ABL tyrosine-kinase inhibitors are also under development to inhibit BCR-ABL mutants resistant to ... "Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr". Cancer Res. 63 (2): 298-303. PMID 12543778. ...
"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat Med. 2 (5): 561-6. ... Based on this work imatinib was developed against chronic myelogenous leukemia (CML) and later gefitinib and erlotinib aiming ... For example, they have substantially improved outcomes in chronic myelogenous leukemia. They are also called tyrphostins, the ... Bcr-Abl tyrosine-kinase inhibitor Protein kinase inhibitor Yaish P, Gazit A, Gilon C, Levitzki A (1988). "Blocking of EGF- ...
... a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based ... Subsequent studies of 449 patients treated during 4 years with ponatinib for chronic phase chronic myelogenous leukemia found ... Approval was also granted for T315I-positive and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia. ... Experts in Chronic Myeloid Leukemia (May 2013). "The price of drugs for chronic myeloid leukemia (CML) is a reflection of the ...
"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia". New England Journal of ... "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nature Medicine. 2 (5): ... a drug that has saved the lives of thousands of patients with chronic myelogenous leukaemia (CML) and gastrointestinal stromal ... a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a ...
1989). "Structural alterations of the BCR and ABL genes in Ph1 positive acute leukemias with rearrangements in the BCR gene ... in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia". Mol ... "A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia". Leukemia. 4 (6 ... 1987). "The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript". Mol. ...
BCR/ABL positive)/(Ph1 positive)/t(9;22)(q34;q11) M9876/3 Atypical chronic myelogenous leukemia BCR/ABL negative Atypical ... NOS M9875/3 Chronic myelogenous leukemia BCR/ABL positive Philadelphia chromosome (Ph1 positive) t(9;22)(q34;q11) Chronic ... NOS Chronic myelogenous leukemia, NOS Chronic granulocytic leukemia, NOS Chronic myelocytic leukemia, NOS M9866/3 Acute ... Chronic lymphocytic leukemia Chronic lymphoid leukemia Chronic lymphatic leukemia M9826/3 Burkitt cell Leukemia (see also M9687 ...
... chronic myeloid leukemia (CML) is comparable to acute myeloid leukemia M2 because it also forms a fusion oncoprotein - BCR-Abl ... The acute myeloid leukemia Kasumi-1 cell line was selected for the experiment due to its AML1-ETO positive characteristics. ... Chi Y, Lindgren V, Quigley S, Gaitonde S (2008). "Acute Myelogenous Leukemia With t(6;9)(p23;q34) and Marrow Basophilia: An ... has had a tremendous effect on stopping cancer progression in the majority of chronic myeloid leukemia patients. BCR-Abl is ...
... which occurs in chronic myelogenous leukemia, and results in production of the BCR-abl fusion protein, an oncogenic tyrosine ... First, there exists a highly positive correlation (Spearman's rho = 0.81; P < 3.5 × 10−8) between the risk of developing cancer ... and miR-29b in chronic lymphocytic leukemia". Blood. 119 (5): 1162-72. doi:10.1182/blood-2011-05-351510. PMC 3277352. PMID ... Thus, the usual consequence of H. pylori infection is chronic asymptomatic gastritis. Because of the usual lack of symptoms, ...
Imatinib (Glivec/Gleevec), an orally administered drug initially marketed for chronic myelogenous leukemia based on bcr-abl ... In the gut, however, a mass staining positive for CD117 is likely to be a GIST, arising from ICC cells. The c-KIT molecule ... of all GISTs are CD117-positive (other possible markers include CD34, DOG-1, desmin, and vimentin). Other cells that show CD117 ...
In both of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML), MSI2 regulates hematopoietic stem cell ... It has been found that MSI2 participates together with BCR-ABL gene to stimulate the progress to the aggressive phase. The ... positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22". Haematologica. 93 (12): 1903-7. ... Chronic myelogenous leukemia (CML) progresses from the initial phase, where differentiated myeloid cells are accumulated, to ...
In chronic myelogenous leukemia (CML), GAB2 interacts with the Bcr-Abl complex and is instrumental in maintaining the oncogenic ... By binding to the p85 subunit of PI3K, and continuing this signaling pathway GAB provides positive feedback for the creation of ... The Grb2/GAB2 complex is recruited to phosphorylated Y177 of the Bcr-Abl complex leading to Bcr-Abl-mediated transformation and ... "Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2". ...
... in complex with an Abl kinase domain (blue). Nilotinib is used to treat chronic myelogenous leukemia (CML), a hematological ... "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat Med. 2 (5): 561-6. ... For example, they have substantially improved outcomes in chronic myelogenous leukemia. They are also called tyrphostins, the ... Based on this work imatinib was developed against chronic myelogenous leukemia (CML)[6] and later gefitinib and erlotinib ...
... "e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts". Leukemia. 16 (8): 1562-3. doi:10.1038/sj.leu. ... The BCR-ABL oncoprotein oligomerisation domain found at the N-terminus of BCR is essential for the oncogenicity of the BCR-ABL ... which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is ... Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ (March 1999). "CRKL binding to BCR-ABL and BCR-ABL transformation". Leuk. ...
As chemotherapy affects cell division, tumors with high growth rates (such as acute myelogenous leukemia and the aggressive ... a genetic lesion found commonly in chronic myelomonocytic leukemia. This fusion protein has enzyme activity that can be ... The FOLFOX study also demonstrated an improvement in treatment outcomes.[22] Positive response increased from 46% in the BSA- ... bcr-abl *Imatinib. *Dasatinib. *Nilotinib. *Ponatinib. *Radotinib. *Src (Bosutinib. *Dasatinib). *Janus kinase *Lestaurtinib ...
Another common example is the class of Bcr-Abl inhibitors, which are used to treat chronic myelogenous leukemia (CML).[4] ... Ehrenreich, Barbara (2009). Bright-sided: How the Relentless Promotion of Positive Thinking Has Undermined America. Henry Holt ... which occurs in chronic myelogenous leukemia and results in production of the BCR-abl fusion protein, an oncogenic tyrosine ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...
... has been used as an engineered "control switch" in chronic myelogenous leukemia models in mice. Engineers were ... "Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette".. ... both Gram-positive and Gram-negative, with a few exceptions, such as Pseudomonas aeruginosa and Proteus spp., which display ... able to develop a retrovirus that induced a particular type of leukemia in mice, and could then "switch" the cancer on and off ...
In the case of Gleevec (Imatinib), which targets the BCR-ABL fusion gene in chronic myeloid leukemia, resistance often develops ... including the Philadelphia chromosome in chronic myelogenous leukemia[14] and translocations in acute myeloblastic leukemia.[15 ... Selective estrogen receptor modulators (SERMs) are a commonly used adjuvant therapy in estrogen-receptor positive (ERα+) breast ... a study of chronic myelogenous leukemia". Am. J. Hum. Genet. 18 (5): 485-503. PMC 1706184 . PMID 5224748.. ...
... in chronic myelogenous leukemia progenitor cells". Blood. 93 (8): 2707-20. doi:10.1182/blood.V93.8.2707. PMID 10194451. Leitges ... and Bcr-Abl". Blood. 89 (8): 2745-56. doi:10.1182/blood.V89.8.2745. PMID 9108392. Liu L, Damen JE, Ware MD, Krystal G (April ... Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C (June 2005). "Molecular basis for positive and negative ... "The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates with the dok1 phosphoprotein in bcr-Abl transformed cells ...
Lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute and chronic myelogenous leukemia, ... BCR-ABL1-positive Chronic neutrophilic leukaemia Polycythaemia vera Primary myelofibrosis Essential thrombocythaemia Chronic ... BCR-ABL 1―like B-lymphoblastic leukaemia/lymphoma with iAMP21 T-lymphoblastic leukaemia/lymphoma Early T-cell precursor ... leg type EBV-positive DLBCL, NOS EBV-positive mucocutaneous ulcer DLBCL associated with chronic inflammation Fibrin-associated ...
... acute lymphocytic leukemia (ALL), Philadelphia chromosome negative chronic myelogenous leukemia (Ph(-)CML), myelodysplastic ... "Nucleotide sequence analysis of human abl and bcr-abl cDNAs". Oncogene. 4 (12): 1477-81. PMID 2687768. Buijs A, Sherr S, van ... "Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3". Blood ... chronic myelomonocytic leukemia, acute myelocytic leukemia, B cell acute lymphoblastic leukemia, mixed phenotype acute leukemia ...
... a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia, which had $ ... "FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative ... On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia and ... Yukhananov, Anna (September 4, 2012). "FDA approves Pfizer leukemia drug". Reuters. "Drug Approval Package". Food and Drug ...
In in vitro studies of chronic myelogenous leukemia (CML), siRNA was used to cleave the fusion protein, BCR-ABL, which prevents ... and positive-strand RNA viruses". Virology. 313 (2): 514-24. doi:10.1016/s0042-6822(03)00341-6. PMID 12954218. Fan Q, Wei C, ... These experiments have suggested that siRNA may be used to combat other respiratory diseases, such as chronic obstructive ... In addition to mucus hypersecretion, chronic inflammation and damaged lung tissue are characteristic of COPD and asthma. The ...
... affinity for the oncofusion protein BCR-Abl which is a strong driver of tumorigenesis in chronic myelogenous leukemia. Although ... "Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum ... Imatinib (Gleevec, also known as STI-571) is approved for chronic myelogenous leukemia, gastrointestinal stromal tumor and some ... Gleevec is most effective targeting BCR-Abl. Other examples of molecular targeted therapeutics targeting mutated oncogenes, ...